Allergic reactions to Gardasil uncommon: study

LONDON (Reuters) - A study of Merck & Co Inc’s cervical cancer vaccine Gardasil found that allergic reactions were uncommon and most young women can tolerate subsequent doses, Australian researchers said on Wednesday.

The research involved 25 Australian girls with suspected hypersensitivity to the vaccine which was administered as part of a national immunization program to all females aged 12 to 26 in the country beginning in 2007.

More than 380,000 doses of the vaccine have been given under the program, Sharon Choo of the Royal Children’s Hospital in Melbourne and colleagues wrote in the British Medical Journal.

“Our clinical recommendation is that females with suspected hypersensitivity to the quadrivalent vaccine should be evaluated before receiving more doses, and any challenges with the same vaccine should be carried out in a supervised setting,” they said.

Choo and colleagues noted some components of Merck’s treatment — such as aluminum salts and yeast — have been associated with allergic reactions.

But skin tests of the 25 girls with suspected hypersensitivity showed that only three of them experienced probable reactions to the jabs.

The researchers also noted that suspected reactions such as hives are often “idiosyncratic” and do not increase the risk of adverse reactions in subsequent shots.

Gardasil and GlaxoSmithKline Plc’s Cervarix are designed to be given to girls and young women to protect against cancer-causing strains of the sexually transmitted human papillomavirus (HPV), which can cause cervical cancer.

Gardasil targets four strains of HPV — two responsible for cervical cancer and two causing the less serious condition of genital warts. Glaxo’s product targets the two cancer strains.

In October, the U.S. Centers for Disease Control and Prevention reported that girls and young women given Gardasil were no more likely than usual to faint, have an allergic reaction, blood clot or other adverse reaction.

The report was based on 375,000 doses of the vaccine given from August 2006 to July 2008 after the agency had received 10,326 reports of adverse events following HPV vaccination in the United States.

(Reporting by Michael Kahn; Editing by Maggie Fox and Elaine Hardcastle)


Related Posts:

By Will Dunham WASHINGTON (Reuters) - A quarter of girls aged 13-17 in the United States received Merck & Co’s Gardasil vaccine last year to protect against the human papillomavirus, which causes cervical cancer, the U.S. government said on Thursday. A report by the Centers for Disease Control and Prevention provided the first look at how many

Full Post: Quarter of adolescent U.S. girls received HPV vaccine

By Lewis Krauskopf and Ransdell Pierson NEW YORK (Reuters) - U.S. health regulators have again withheld approval for the use of Merck & Co Inc’s Gardasil cervical cancer vaccine by women aged 27 to 45, asking for longer-term clinical data, the drugmaker said on Friday. The U.S. Food and Drug Administration recommended Merck submit data when a

Full Post: Gardasil again denied approval for women 27-45

NEW YORK (Reuters) - U.S. health regulators want longer-term data on the use of Merck & Co’s Gardasil cervical cancer vaccine in an older group of women before they will approve the vaccine for those women, the drugmaker said on Friday. The U.S. Food and Drug Administration has issued a second complete response letter to Merck

Full Post: More data sought for Merck’s Gardasil in older women

By Maggie Fox, Health and Science Editor WASHINGTON (Reuters) - A vaccine designed to protect women and girls from cervical cancer caused by a wart virus may protect men, too, maker Merck and Co reported on Thursday. The Gardasil vaccine was 90 percent effective in preventing lesions, mostly sexually transmitted warts, caused by the virus in men,

Full Post: Merck vaccine protects men from wart virus, too

By Megan Rauscher NEW YORK (Reuters Health) - Even in an influenza season where there is not an optimal match between circulating strains of influenza and the strains contained in the influenza vaccine, the vaccine is likely to significantly protect young children, ages 6 to 59 months, against influenza, new research indicates. Influenza vaccine effectiveness has not

Full Post: Influenza vaccine effective in young children

Site Navigation

Most Read